PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ijpsychHomeCurrent issueInstructionsSubmit article
 
Indian J Psychiatry. 2003 Apr-Jun; 45(2): 5–14.
PMCID: PMC2952148

Glucocorticoid receptor dysfunction: consequences for the pathophysiology and treatment of mood disorders

Abstract

Background:

Hypothalamic-pituitary-adrenal (HPA) axis dysfunction in mood disorders is one of the most robust findings in biological psychiatry. However, considerable debate surrounds the nature of the core abnormality, its cause, consequences and treatment implications.

Aims:

To review the evidence for the role of HPA axis dysfunction in the pathophysiology of mood disorders with particular reference to corticosteroid receptor pathology.

Methods:

A selective review of the published literature in this field, focusing on human studies.

Results:

The nature of basal HPA axis dysregulation described in both manic and depressed bipolars appears to be similar to those described in MDD. But studies using the dexamethasone/ corticotropin releasing hormone (dex/CRH) test and dexamethasone suppression test (DST) have shown that HPA axis dysfunction is more prevalent in bipolar than in unipolar disorder. There is robust evidence for corticotropin releasing hormone (CRH) hyperdrive and glucocorticoid receptor (GR) dysfunction in mood disorders, with increasing evidence for disorders within the AVP system.

Conclusion:

HPA axis dysfunction is prevalent in patients with mood disorder, particularly those with psychotic disorders and bipolar affective disorder. This may be secondary to genetic factors, early life adversities or both. Dysfunction of GR may be the underlying abnormality and preliminary findings suggest that it is a potential target for novel therapies.

Declaration of interest:

None

Keywords: Mood disorders, pathophysiology, Glncocorticoid Receptor

Full Text

The Full Text of this article is available as a PDF (569K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Amsterdam JD, Maislin G, Winokur A, Berwish N, Kling M, Gold P. The oCRH stimulation test before and after clinical recovery from depression. J Affect Disord. 1988 May-Jun;14(3):213–222. [PubMed]
  • Amsterdam JD, Winokur A, Abelman E, Lucki I, Rickels K. Cosyntropin (ACTH alpha 1-24) stimulation test in depressed patients and healthy subjects. Am J Psychiatry. 1983 Jul;140(7):907–909. [PubMed]
  • Antoni FA. Hypothalamic control of adrenocorticotropin secretion: advances since the discovery of 41-residue corticotropin-releasing factor. Endocr Rev. 1986 Nov;7(4):351–378. [PubMed]
  • Arana GW, Barreira PJ, Cohen BM, Lipinski JF, Fogelson D. The dexamethasone suppression test in psychotic disorders. Am J Psychiatry. 1983 Nov;140(11):1521–1523. [PubMed]
  • Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 1999 Jan;160(1):1–12. [PubMed]
  • Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol. 2001 Oct;21(5):516–521. [PubMed]
  • Brown ES, Bobadilla L, Rush AJ. Ketoconazole in bipolar patients with depressive symptoms: a case series and literature review. Bipolar Disord. 2001 Feb;3(1):23–29. [PubMed]
  • Cardno Alastair G, Rijsdijk Frühling V, Sham Pak C, Murray Robin M, McGuffin Peter. A twin study of genetic relationships between psychotic symptoms. Am J Psychiatry. 2002 Apr;159(4):539–545. [PubMed]
  • Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression. II. Discrimination of depressed from nondepressed patients. Arch Gen Psychiatry. 1976 Sep;33(9):1051–1058. [PubMed]
  • Cervantes P, Gelber S, Kin FN, Nair VN, Schwartz G. Circadian secretion of cortisol in bipolar disorder. J Psychiatry Neurosci. 2001 Nov;26(5):411–416. [PMC free article] [PubMed]
  • Cole TJ, Blendy JA, Monaghan AP, Krieglstein K, Schmid W, Aguzzi A, Fantuzzi G, Hummler E, Unsicker K, Schütz G. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev. 1995 Jul 1;9(13):1608–1621. [PubMed]
  • Cole TJ, Myles K, Purton JF, Brereton PS, Solomon NM, Godfrey DI, Funder JW. GRKO mice express an aberrant dexamethasone-binding glucocorticoid receptor, but are profoundly glucocorticoid resistant. Mol Cell Endocrinol. 2001 Feb 28;173(1-2):193–202. [PubMed]
  • Coplan JD, Andrews MW, Rosenblum LA, Owens MJ, Friedman S, Gorman JM, Nemeroff CB. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders. Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1619–1623. [PubMed]
  • Davis M. The role of the amygdala in fear and anxiety. Annu Rev Neurosci. 1992;15:353–375. [PubMed]
  • de Kloet ER, Oitzl MS, Joëls M. Functional implications of brain corticosteroid receptor diversity. Cell Mol Neurobiol. 1993 Aug;13(4):433–455. [PubMed]
  • De Kloet ER, Reul JM. Feedback action and tonic influence of corticosteroids on brain function: a concept arising from the heterogeneity of brain receptor systems. Psychoneuroendocrinology. 1987;12(2):83–105. [PubMed]
  • De Kloet ER, Vreugdenhil E, Oitzl MS, Joëls M. Brain corticosteroid receptor balance in health and disease. Endocr Rev. 1998 Jun;19(3):269–301. [PubMed]
  • Dean CE. Prasterone (DHEA) and mania. Ann Pharmacother. 2000 Dec;34(12):1419–1422. [PubMed]
  • DeBattista C, Posener JA, Kalehzan BM, Schatzberg AF. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2000 Aug;157(8):1334–1337. [PubMed]
  • Dubrovsky B. Effects of adrenal cortex hormones on limbic structures: some experimental and clinical correlations related to depression. J Psychiatry Neurosci. 1993 Jan;18(1):4–16. [PMC free article] [PubMed]
  • Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Brain Res Rev. 1990 May-Aug;15(2):71–100. [PubMed]
  • Erkut ZA, Pool C, Swaab DF. Glucocorticoids suppress corticotropin-releasing hormone and vasopressin expression in human hypothalamic neurons. J Clin Endocrinol Metab. 1998 Jun;83(6):2066–2073. [PubMed]
  • Ferrier IN, Stanton BR, Kelly TP, Scott J. Neuropsychological function in euthymic patients with bipolar disorder. Br J Psychiatry. 1999 Sep;175:246–251. [PubMed]
  • GIBBONS JL. CORTISOL SECRETION RATE IN DEPRESSIVE ILLNESS. Arch Gen Psychiatry. 1964 Jun;10:572–575. [PubMed]
  • Gold PW, Chrousos G, Kellner C, Post R, Roy A, Augerinos P, Schulte H, Oldfield E, Loriaux DL. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am J Psychiatry. 1984 May;141(5):619–627. [PubMed]
  • Goodwin FK. The biology of depression: conceptual issues. Adv Biochem Psychopharmacol. 1984;39:11–26. [PubMed]
  • Gould E, Tanapat P, Rydel T, Hastings N. Regulation of hippocampal neurogenesis in adulthood. Biol Psychiatry. 2000 Oct 15;48(8):715–720. [PubMed]
  • Graham PM, Booth J, Boranga G, Galhenage S, Myers CM, Teoh CL, Cox LS. The dexamethasone suppression test in mania. J Affect Disord. 1982 Sep;4(3):201–211. [PubMed]
  • Greden JF, DeVigne JP, Albala AA, Tarika J, Buttenheim M, Eiser A, Carroll BJ. Serial dexamethasone suppression tests among rapidly cycling bipolar patients. Biol Psychiatry. 1982 Apr;17(4):455–462. [PubMed]
  • Harris TO, Borsanyi S, Messari S, Stanford K, Cleary SE, Shiers HM, Brown GW, Herbert J. Morning cortisol as a risk factor for subsequent major depressive disorder in adult women. Br J Psychiatry. 2000 Dec;177:505–510. [PubMed]
  • Heim C, Newport DJ, Bonsall R, Miller AH, Nemeroff CB. Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse. Am J Psychiatry. 2001 Apr;158(4):575–581. [PubMed]
  • Heim C, Newport DJ, Miller AH, Nemeroff CB. Long-term neuroendocrine effects of childhood maltreatment. JAMA. 2000 Nov 8;284(18):2321–2321. [PubMed]
  • Heuser IJ, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Dettling M, Yassouridis A, Holsboer F. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry. 1996 Jan;153(1):93–99. [PubMed]
  • Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res. 1994 Jul-Aug;28(4):341–356. [PubMed]
  • Inskip HM, Harris EC, Barraclough B. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br J Psychiatry. 1998 Jan;172:35–37. [PubMed]
  • Jacobson L, Sapolsky R. The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr Rev. 1991 May;12(2):118–134. [PubMed]
  • Jaeckle RS, Kathol RG, Lopez JF, Meller WH, Krummel SJ. Enhanced adrenal sensitivity to exogenous cosyntropin (ACTH alpha 1-24) stimulation in major depression. Relationship to dexamethasone suppression test results. Arch Gen Psychiatry. 1987 Mar;44(3):233–240. [PubMed]
  • Jones MT, Gillham B, Campbell EA, Al-Taher AR, Chuang TT, Di Sciullo A. Pharmacology of neural pathways affecting CRH secretion. Ann N Y Acad Sci. 1987;512:162–175. [PubMed]
  • Kaminska M, Harris J, Gijsbers K, Dubrovsky B. Dehydroepiandrosterone sulfate (DHEAS) counteracts decremental effects of corticosterone on dentate gyrus LTP. Implications for depression. Brain Res Bull. 2000 Jun;52(3):229–234. [PubMed]
  • Kay JH, Altshuler LL, Ventura J, Mintz J. Prevalence of axis II comorbidity in bipolar patients with and without alcohol use disorders. Ann Clin Psychiatry. 1999 Dec;11(4):187–195. [PubMed]
  • Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994 Jan;51(1):8–19. [PubMed]
  • Kirschbaum C, Hellhammer DH. Salivary cortisol in psychoneuroendocrine research: recent developments and applications. Psychoneuroendocrinology. 1994;19(4):313–333. [PubMed]
  • Kline MD, Jaggers ED. Mania onset while using dehydroepiandrosterone. Am J Psychiatry. 1999 Jun;156(6):971–971. [PubMed]
  • Laaris N, Le Poul E, Laporte AM, Hamon M, Lanfumey L. Differential effects of stress on presynaptic and postsynaptic 5-hydroxytryptamine-1A receptors in the rat brain: an in vitro electrophysiological study. Neuroscience. 1999;91(3):947–958. [PubMed]
  • Ladd CO, Owens MJ, Nemeroff CB. Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation. Endocrinology. 1996 Apr;137(4):1212–1218. [PubMed]
  • Lauer CJ, Schreiber W, Modell S, Holsboer F, Krieg JC. The Munich vulnerability study on affective disorders: overview of the cross-sectional observations at index investigation. J Psychiatr Res. 1998 Nov-Dec;32(6):393–401. [PubMed]
  • Liebsch G, Landgraf R, Engelmann M, Lörscher P, Holsboer F. Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. J Psychiatr Res. 1999 Mar-Apr;33(2):153–163. [PubMed]
  • Liebsch G, Wotjak CT, Landgraf R, Engelmann M. Septal vasopressin modulates anxiety-related behaviour in rats. Neurosci Lett. 1996 Oct 18;217(2-3):101–104. [PubMed]
  • Lupien SJ, McEwen BS. The acute effects of corticosteroids on cognition: integration of animal and human model studies. Brain Res Brain Res Rev. 1997 Jun;24(1):1–27. [PubMed]
  • Markowitz JS, Carson WH, Jackson CW. Possible dihydroepiandrosterone-induced mania. Biol Psychiatry. 1999 Jan 15;45(2):241–242. [PubMed]
  • McAllister-Williams RH, Ferrier IN, Young AH. Mood and neuropsychological function in depression: the role of corticosteroids and serotonin. Psychol Med. 1998 May;28(3):573–584. [PubMed]
  • McElroy SL, Altshuler LL, Suppes T, Keck PE, Jr, Frye MA, Denicoff KD, Nolen WA, Kupka RW, Leverich GS, Rochussen JR, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry. 2001 Mar;158(3):420–426. [PubMed]
  • McGuffin Peter, Rijsdijk Fruhling, Andrew Martin, Sham Pak, Katz Randy, Cardno Alastair. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry. 2003 May;60(5):497–502. [PubMed]
  • McQuade R, Young AH. Future therapeutic targets in mood disorders: the glucocorticoid receptor. Br J Psychiatry. 2000 Nov;177:390–395. [PubMed]
  • Modell S, Lauer CJ, Schreiber W, Huber J, Krieg JC, Holsboer F. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology. 1998 Apr;18(4):253–262. [PubMed]
  • Nemeroff CB, Widerlöv E, Bissette G, Walléus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science. 1984 Dec 14;226(4680):1342–1344. [PubMed]
  • Nemeroff CB. The role of corticotropin-releasing factor in the pathogenesis of major depression. Pharmacopsychiatry. 1988 Mar;21(2):76–82. [PubMed]
  • Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW, Loriaux DL. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab. 1985 Sep;61(3):536–540. [PubMed]
  • Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry. 2001 Mar 1;49(5):391–404. [PubMed]
  • Plotsky PM, Meaney MJ. Early, postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult rats. Brain Res Mol Brain Res. 1993 May;18(3):195–200. [PubMed]
  • Purba JS, Hoogendijk WJ, Hofman MA, Swaab DF. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry. 1996 Feb;53(2):137–143. [PubMed]
  • Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology. 1994 Oct;60(4):436–444. [PubMed]
  • Rush AJ, Giles DE, Schlesser MA, Orsulak PJ, Parker CR, Jr, Weissenburger JE, Crowley GT, Khatami M, Vasavada N. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry. 1996 Oct;57(10):470–484. [PubMed]
  • Rybakowski JK, Twardowska K. The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J Psychiatr Res. 1999 Sep-Oct;33(5):363–370. [PubMed]
  • Sachar EJ. Twenty-four-hour cortisol secretory patterns in depressed and manic patients. Prog Brain Res. 1975;42:81–91. [PubMed]
  • Sapolsky RM, Krey LC, McEwen BS. The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocr Rev. 1986 Aug;7(3):284–301. [PubMed]
  • Sassi RB, Nicoletti M, Brambilla P, Harenski K, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC. Decreased pituitary volume in patients with bipolar disorder. Biol Psychiatry. 2001 Aug 15;50(4):271–280. [PubMed]
  • Schatzberg AF, Rothschild AJ, Langlais PJ, Bird ED, Cole JO. A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res. 1985;19(1):57–64. [PubMed]
  • Schmider J, Lammers CH, Gotthardt U, Dettling M, Holsboer F, Heuser IJ. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol Psychiatry. 1995 Dec 15;38(12):797–802. [PubMed]
  • Scott LV, Dinan TG. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. Life Sci. 1998;62(22):1985–1998. [PubMed]
  • Solomon DA, Keller MB, Leon AC, Mueller TI, Shea MT, Warshaw M, Maser JD, Coryell W, Endicott J. Recovery from major depression. A 10-year prospective follow-up across multiple episodes. Arch Gen Psychiatry. 1997 Nov;54(11):1001–1006. [PubMed]
  • Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F, Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet. 1998 Jun;19(2):162–166. [PubMed]
  • Vale W, Rivier C, Brown MR, Spiess J, Koob G, Swanson L, Bilezikjian L, Bloom F, Rivier J. Chemical and biological characterization of corticotropin releasing factor. Recent Prog Horm Res. 1983;39:245–270. [PubMed]
  • Valentino RJ, Foote SL, Page ME. The locus coeruleus as a site for integrating corticotropin-releasing factor and noradrenergic mediation of stress responses. Ann N Y Acad Sci. 1993 Oct 29;697:173–188. [PubMed]
  • van der Lely AJ, Foeken K, van der Mast RC, Lamberts SW. Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann Intern Med. 1991 Jan 15;114(2):143–144. [PubMed]
  • Vieta E, Gasto C, Martinez de Osaba MJ, Nieto E, Canto TJ, Otero A, Vallejo J. Prediction of depressive relapse in remitted bipolar patients using corticotrophin-releasing hormone challenge test. Acta Psychiatr Scand. 1997 Mar;95(3):205–211. [PubMed]
  • Vieta E, Martínez-De-Osaba MJ, Colom F, Martínez-Arán A, Benabarre A, Gastó C. Enhanced corticotropin response to corticotropin-releasing hormone as a predictor of mania in euthymic bipolar patients. Psychol Med. 1999 Jul;29(4):971–978. [PubMed]
  • Webster MJ, Knable MB, O'Grady J, Orthmann J, Weickert CS. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry. 2002;7(9):985–924. [PubMed]
  • Wehr TA, Goodwin FK. Do antidepressants cause mania? Psychopharmacol Bull. 1987;23(1):61–65. [PubMed]
  • Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA. 1996 Jul 24;276(4):293–299. [PubMed]
  • Whalley LJ, Christie JE, Blackwood DH, Bennie J, Dick H, Blackburn IM, Fink G. Disturbed endocrine function in the psychoses. I: Disordered homeostasis or disease process? Br J Psychiatry. 1989 Oct;155:455–461. [PubMed]
  • White-Gbadebo D, Hamm RJ. Chronic corticosterone treatment potentiates deficits following traumatic brain injury in rats: implications for aging. J Neurotrauma. 1993 Fall;10(3):297–306. [PubMed]
  • Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, Roberts E. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry. 1999 Apr;156(4):646–649. [PubMed]
  • Wolkowitz OM, Reus VI, Roberts E, Manfredi F, Chan T, Raum WJ, Ormiston S, Johnson R, Canick J, Brizendine L, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry. 1997 Feb 1;41(3):311–318. [PubMed]
  • Young Allan H, Gallagher Peter, Porter Richard J. Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. Am J Psychiatry. 2002 Jul;159(7):1237–1239. [PubMed]
  • Young AH, Sahakian BJ, Robbins TW, Cowen PJ. The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Psychopharmacology (Berl) 1999 Aug;145(3):260–266. [PubMed]
  • Young AH, Sharpley AL, Campling GM, Hockney RA, Cowen PJ. Effects of hydrocortisone on brain 5-HT function and sleep. J Affect Disord. 1994 Oct;32(2):139–146. [PubMed]
  • Young EA, Carlson NE, Brown MB. Twenty-four-hour ACTH and cortisol pulsatility in depressed women. Neuropsychopharmacology. 2001 Aug;25(2):267–276. [PubMed]
  • Zarate CA, Jr, Tohen M, Land M, Cavanagh S. Functional impairment and cognition in bipolar disorder. Psychiatr Q. 2000 Winter;71(4):309–329. [PubMed]
  • Zobel AW, Nickel T, Künzel HE, Ackl N, Sonntag A, Ising M, Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res. 2000 May-Jun;34(3):171–181. [PubMed]

Articles from Indian Journal of Psychiatry are provided here courtesy of Medknow Publications